Want to see NGNE full AI Analyst Report?
Total Valuation
Neurogene has a market cap or net worth of $768.64M. The enterprise value is $492.21.
Market Cap$768.64M
Enterprise Value$492.21
Share Statistics
Neurogene has 20,011,381 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding20,011,381
Owned by Insiders7.35%
Owned by Institutions54.56%
Financial Efficiency
Neurogene’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -37.50%.
Return on Equity (ROE)-0.34
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-37.50%
Return on Capital Employed (ROCE)-0.38
Revenue Per Employee0.00
Profits Per Employee-689.70K
Employee Count131
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Neurogene is ―. Neurogene’s PEG ratio is 5.20.
PE Ratio―
PS Ratio0.00
PB Ratio1.65
Price to Fair Value1.65
Price to FCF-5.57
Price to Operating Cash Flow-9.90
PEG Ratio5.20
Income Statement
In the last 12 months, Neurogene had revenue of 0.00 and earned -90.35M in profits. Earnings per share was -4.24.
Revenue0.00
Gross Profit-3.19M
Operating Income-103.21M
Pretax Income-90.35M
Net Income-90.35M
EBITDA-87.25M
Earnings Per Share (EPS)-4.24
Cash Flow
In the last 12 months, operating cash flow was -86.24M and capital expenditures -875.40K, giving a free cash flow of -87.11M billion.
Operating Cash Flow-86.24M
Free Cash Flow-87.11M
Free Cash Flow per Share-4.35
Dividends & Yields
Neurogene pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta3.12
52-Week Price Change100.96%
50-Day Moving Average35.45
200-Day Moving Average25.76
Relative Strength Index (RSI)55.57
Average Volume (3m)270.69K
Important Dates
Neurogene upcoming earnings date is Nov 23, 2026, Before Open (Confirmed).
Last Earnings DateAug 11, 2026
Next Earnings DateNov 23, 2026
Ex-Dividend Date―
Financial Position
Neurogene as a current ratio of 16.56, with Debt / Equity ratio of 3.84%
Current Ratio16.56
Quick Ratio16.56
Debt to Market Cap0.02
Net Debt to EBITDA1.08
Interest Coverage Ratio-20.64K
Taxes
In the past 12 months, Neurogene has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Neurogene EV to EBITDA ratio is -3.92, with an EV/FCF ratio of -4.37.
EV to Sales0.00
EV to EBITDA-3.92
EV to Free Cash Flow-4.37
EV to Operating Cash Flow-4.43
Balance Sheet
Neurogene has $225.39M in cash and marketable securities with $8.35M in debt, giving a net cash position of $217.05M billion.
Cash & Marketable Securities$225.39M
Total Debt$8.35M
Net Cash$217.05M
Net Cash Per Share$10.85
Tangible Book Value Per Share$12.51
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Neurogene is $81.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$81.83
Price Target Upside100.38% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast-18.84%